Supplementary Table S3. Baseline clinical and pathological characteristics of patients in the discovery cohort.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | All#N=36 | Innate resistanceN=20 | Clinical benefitN=15 | *P\** |
| Age, n (%)<4040-69>70 | 9 (25.0%)25 (69.4%)2 (5.6%) | 6 (30.0%)13 (65.0%)1 (5.0%) | 2 (13.3%)12 (80.0%)1 (6.7%) | 0.609 |
| Stage at diagnosis, n (%) I II III IV | 5 (13.9%)19 (52.8%)3 (8.3%)9 (25.0%) | 3 (15.0%)10 (50.0%)3 (15.0%)4 (20.0%) | 2 (13.3%)9 (60.0%)04 (26.7%) | 0.534 |
| ER/PR statusER+PR-ER+PR+ ER-PR+ | 12 (33.3%)23 (63.9%)1 (2.8%) | 4 (20.0%)15 (75.0%)1 (5.0%) | 8 (53.3%)7 (46.7%)0 | 0.071 |
| Visceral metastasis Yes No | 27 (75.0%)9 (25.0%) | 16 (80%)4 (20.0%) | 10 (66.7%)5 (33.3%) | 0.451 |
| Bone-only metastasis Yes No | 1 (2.8%)35 (97.2%) | 020 (100.0%) | 1 (6.7%)14 (93.3%) | 0.429 |
| Combined endocrine therapy Fulvestrant Letrozole Exemestane Anastrozole | 18 (50.0%)10 (27.8%)5 (13.9%)3 (8.3%) | 11 (55.0%)4 (20.0%)3 (15.0%)2 (10.0%) | 6 (40.0%)6 (40.0%)2 (13.3%)1 (6.7%) | 0.665 |
| Previous lines of therapy, N (%) 0-1 2-4 >5 | 8 (22.2%)26 (72.2%)2 (5.6%) | 4 (20.0%)15 (75.0%)1 (5.0%) | 4 (26.7%)10 (66.7%)1 (6.7%) | 0.864 |
| Documented sensitivity to prior hormone therapy Yes No | 23 (63.9%)13 (36.1%) | 12 (60.0%)8 (40.0%) | 10 (66.7%)5 (33.3%) | 0.737 |
| #one out of 36 patients interrupted treatment due to toxicity, thus was not included in the subsequent data sets for efficacy evaluation \*compared between patients with innate resistance and those benefit from CDK4/6 inhibitorER, estrogen receptors; PR, progesterone receptors. |